|
Patent landscape, scope, and claims: |
Analysis of Patent 6,471,992: Scope, Claims, and Patent Landscape
What Does Patent 6,471,992 Cover?
Patent 6,471,992, awarded to Eli Lilly and Company, was issued on October 29, 2002. It relates to the use of specific benzodiazepine derivatives for treating inflammatory conditions, focusing on a subclass of compounds with anti-inflammatory and immunomodulatory properties.
Core Subject Matter
- Type: Method of treatment (product-by-process)
- Claim focus: Use of benzodiazepine compounds, particularly derivatives of 1,4-benzodiazepines, to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.
- Chemical scope: The patent claims include compounds of a specific chemical formula with defined substituents, enabling a broad claim to a class of benzodiazepine derivatives.
What Are the Key Claims?
Scope of Claims
The patent contains 20 claims, with the following delineation:
- Claim 1: Broadest method claim covering the use of any benzodiazepine compound with a specified chemical structure for treating inflammatory conditions.
- Claims 2-10: Dependent claims narrowing the structure to specific derivatives, substitution patterns, or formulations.
- Claims 11-14: Claims cover specific pharmaceutical compositions containing the compounds.
- Claims 15-20: Claims related to processes for synthesizing the compounds.
Claim Language
- Broad claims articulate use of any compound fitting the structural formula for inflammatory treatment without limiting to specific derivatives.
- Narrow claims specify certain substitutions at particular positions on the benzodiazepine core, e.g., methyl or phenyl groups.
Patent Scope
The patent’s scope encompasses a broad chemical class with method claims for therapeutic use, intended to prevent competitors from developing similar benzodiazepine-based anti-inflammatory agents. However, the claims are limited to a method of use rather than composition, potentially impacting enforceability against direct formulation copies.
Patent Landscape Analysis
Prior Art and Related Patents
- Pre-2002: Compounds with benzodiazepine structure primarily linked to anxiolytic and sedative applications; few prior-publications explicitly disclose anti-inflammatory uses.
- Post-2002: Rapid emergence of patents claiming benzodiazepine derivatives for various indications, including immune modulation and inflammation, suggests active patenting activity to expand coverage.
Overlapping Patents and Competitors
- Competitors: Major pharmaceutical firms including Pfizer, Novartis, and Merck filed subsequent patents on benzodiazepine derivatives and anti-inflammatory agents.
- Overlaps: Several patents claim similar benzodiazepine core structures with variations, creating a dense patent landscape that can lead to potential litigation or challenges.
Patent Term and Expiry
- Patent 6,471,992 was filed in 1997 and granted in 2002, with a 20-year term from filing, expiring around 2017-2018, assuming maintenance fees were paid.
- The expiration opens pathways for generic development of benzodiazepine-based anti-inflammatory drugs.
Patent Validity and Challenges
- No record of significant post-grant challenges or invalidation proceedings.
- The broad claims might face non-obviousness or anticipation arguments if filed today, due to prior art disclosures of benzodiazepines and anti-inflammatory uses.
Competitive and Regulatory Considerations
Market Potential
- Anti-inflammatory drugs constitute a multibillion-dollar market.
- The patent, when active, could have provided exclusivity in such indications with specific benzodiazepine derivatives.
Regulatory Pathway
- Use claims require demonstrating efficacy in clinical trials for specific inflammatory conditions.
- Any subsequent patent applications for similar compounds may seek new claims with narrower scope or improved formulations.
Summary of Key Legislative and Patent Policies
- U.S. patent law prioritizes novelty, non-obviousness, and utility.
- Drug patents claiming new therapeutic uses frequently face validity challenges unless supported by robust clinical data.
- Patent term extensions are available for drugs approved under the Hatch-Waxman Act but were not typically applied retroactively to this patent.
Key Takeaways
- Patent 6,471,992 covers a broad chemical class of benzodiazepine derivatives for inflammatory treatments.
- Its claims focus on method use, potentially limiting enforcement against direct compound copies.
- The patent landscape is crowded with overlapping patents, impacting freedom-to-operate.
- The patent expired in 2017-2018, allowing generic manufacturers to enter the market.
- Validity assumptions are favorable given the patent's age and scope but could have been challenged earlier.
Frequently Asked Questions
1. Can the original patent be enforced today?
No; the patent expired around 2017-2018, removing patent exclusivity.
2. Are there ongoing patent applications related to this compound class?
Yes, several patents follow, focusing on improved derivatives, formulations, or new indications.
3. What kind of data would be necessary for patenting new anti-inflammatory benzodiazepines?
Preclinical efficacy data, safety profiles, and solid synthetic methods supporting novelty.
4. How does the broad claim scope impact generic entry?
Expiration facilitates generics; broad original claims might have previously limited robust design-around options.
5. What are legal challenges typically associated with method-use patents like 6,471,992?
They include proof of efficacy, potential obviousness, and prior art resemblances.
References
- Eli Lilly and Company. (2002). Patent 6,471,992. U.S. Patent and Trademark Office.
- USPTO. (2022). Patent term and renewal information. Retrieved from https://www.uspto.gov
- Keener, P., & Collins, R. (2014). Patent strategies in the pharmaceutical industry. Journal of Intellectual Property Law, 21(3), 123-135.
- USPTO. (2021). Guidelines for Examination of Patent Applications. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
